

Cardiac sarcoidosis manifesting with atrioventricular block and intracardiac masses: case report and literature review

Noah Newman ()¹*, Mariana Garcia¹, Frehiywot Ayele², Prateek Gandiga², and Kunal Bhatt¹

¹Department of Cardiology Atlanta, Emory University School of Medicine, 100 Woodruff Circle, Atlanta, GA 30322, USA; and ²Department of Rheumatology Atlanta, Emory University School of Medicine, Atlanta, GA, USA

Received 9 April 2024; revised 30 June 2024; accepted 5 August 2024; online publish-ahead-of-print 12 August 2024

Background	Cardiac sarcoidosis (CS) typically manifests with atrioventricular block (AVB), ventricular arrhythmias, or heart failure. Intracardiac masses due to CS are rare, and there is both a paucity of evidence and guidelines of how manage them.
Case summary	We describe a 45-year-old woman who presented with palpitations and dyspnoea on exertion found to have second-degree AVB. Further work-up noted two right atrial masses that, following excision and pathology, were identified as CS. Within several months of immunosuppressive treatment, imaging and device reports demonstrated mass resolution without arrhythmia recurrence.
Discussion	Intracardiac masses are a rare manifestation of CS. Immunosuppressive therapy remains the mainstay of treatment, with consid- eration of mass resection for diagnostic purposes.
Keywords	Case report • Cardiac sarcoidosis • Arrhythmia • Infiltrative cardiomyopathy • Intracardiac mass • Multimodality imaging
ESC curriculum	2.1 Imaging modalities • 2.3 Cardiac magnetic resonance • 2.5 Nuclear techniques • 6.5 Cardiomyopathy

Learning points

- To review the various manifestations of cardiac sarcoidosis to expedite time to diagnosis.
- To identify medical and surgical management options for cardiac sarcoid masses.

Introduction

Sarcoidosis is a multisystem granulomatous disease of unknown aetiology that most commonly affects the lungs, skin, lymph nodes, and eyes. It has a large economic impact with estimated direct medical costs as high as \$8.7 billion in the USA.¹ Cardiac sarcoidosis (CS) can occur either as part of systemic sarcoidosis or as an isolated

entity. While CS is much less common, imaging and autopsy studies suggest that this may be because many cases are clinically silent and therefore go unrecognized.² Cardiac sarcoidosis most commonly causes either asymptomatic or symptomatic atrioventricular block (AVB), but other frequent presentations include ventricular arrhythmias and heart failure.^{2,3} Notably, CS-related intracardiac masses are exceedingly rare.

* Corresponding author. Tel: 404 729 2875, Email: nnewma2@emory.edu

Handling Editor: Andreas Giannopoulos

Compliance Editor: Marta Peverelli

Peer-reviewers: Arif Albulushi; Erick Alexanderson Rosas

[©] The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Summary figure

Date	Event
Day 1	She presents with palpitations and exertional dyspnoea. A 12-lead ECG shows second-degree AVB (Figure 1). She is admitted for further work-up and pacemaker placement.
Week 1	A CMR revealed two right atrial masses (<i>Figure 2A</i>). A subsequent base-to-skull FDG-cPET is performed and shows that the atrial masses are FDG-avid (<i>Figure 2B</i>).
Week 2	Two EMBs are performed but are either unremarkable or inconclusive.
Week 6	Both right atrial masses are removed. H&E stains reveal non-caseating granulomas (<i>Figure 2C</i> and <i>D</i>), and she is diagnosed with CS. Several days later, a dual-chamber ICD is placed. She is discharged with prednisone oral 30 mg daily.
Month 3	She receives the first dose of infliximab. A couple of weeks later, she starts methotrexate to prevent HACA formation.
Month 4	A device check is performed. It shows no atrial or ventricular arrhythmias.
Month 6	A repeat FDG-cPET shows no evidence of sarcoidosis, and the previously noted FDG-avid lesions in the atria are no longer present (Figure 3).

Presentation

A 45-year-old woman with a history of well-controlled Graves' disease presented with palpitations and dyspnoea on minimal exertion. Her family history was notable for a brother and sister with lupus, and her father has sarcoidosis. On presentation, she was normotensive, bradycardic with a heart rate of 38 b.p.m., eupnoeic, normoxaemic, and afebrile. Her cardiac exam noted bradycardia with an irregular rhythm but good pulses; pulmonary, musculoskeletal, neurologic, and cutaneous exams were unremarkable. She was admitted for further work-up.

A 12-lead ECG demonstrated a heart rate of 48 b.p.m. with seconddegree AVB (*Figure 1*). She was admitted for further work-up and pacemaker placement for symptomatic bradycardia. A transthoracic echocardiography (TTE) demonstrated a left ventricular ejection fraction (LVEF) of 60–65% and suggested two intracardiac masses that were further characterized on cardiac magnetic resonance imaging (CMR) to be in the right atrium and have delayed gadolinium enhancement (*Figure 2A*). An ¹⁸F-fluorodeoxyglucose-positron cardiac positron emission tomography (FDG-cPET) demonstrated that the atrial masses were FDG-avid (*Figure 2B*). She received an endobronchial lung biopsy plus a transbronchial needle aspiration of a left hilar lymph node, which were negative for malignant cells or organisms. Two subsequent endomyocardial biopsies (EMB) were either negative or non-diagnostic as well.

Following multidisciplinary discussions, the involved specialties agreed to pursue further tissue sampling. Given the failure of multiple EMBs,






Figure 1 Initial ECG. ECG at initial presentation demonstrating HR 48 b.p.m. with second-degree AVB. AVB, atrioventricular block; ECG, electrocardiogram; HR, heart rate.








Figure 3 Follow-up FGD-cPET. A follow-up scan performed several months following the initiation of immunosuppressive treatment demonstrated that the initial FGD-avid foci in the right atria were no longer visible. FDG-cPET, ¹⁸F-fluorodeoxyglucose-positron cardiac positron emission tomography.

	Extra-cardiac Advanced Therapy (duration if Outcome involvement? imaging specified)	Mediastinal None Prednisone 60 mg daily Reduction in size of masses lymphadenopathy	Lungs None Not mentioned Not mentioned	None Gallium Surgical resection Not mentioned scintigraphy	None CMR and gallium Permanent pacemaker, Mass size reduction, AVB scintigraphy prednisolone 30 mg daily recovery to first-degree for 4 weeks AVB	Para-hilar lymph CMR Steroids Arrhythmia resolution nodes	Lungs, liver, and CMR and Prednisolone 40 mg daily Not mentioned spleen FDG-PET tapered by 5 mg every two weeks	Not specified CMR and Not mentioned Not mentioned FDG-PET	Eyes CMR, FDG-PET, Prednisolone 30 mg daily, Mass size reduction, and gallium tapered to 7.5 mg daily resolution of AVB scintigraphy maintenance	Mediastinal lymph CMR and Prednisolone 30 mg daily Mass size reduction, nodes FDG-PET resolution of AVB	FDG-PET Permanent pacemaker, N prednisolone 30 mg daily tapered to 7.5 mg daily
		rricular Mediastinal Iymphadenopathy		None	None		5	Not specified Cr	h egree	Ð	Lungs
om PubMed	Mass(es) details Cardiac	Pericardial space, RA, and LV lateral wall	RV along IVS Ventricula	LA arising from the Third-degree AVB, reduced interatrial ejection fraction (35%) septum (34 x 38 mm)	Basal IVS Third-degree AVB	RV along IVS Ventricula	RA (12×12 mm) First-degr progres third-de	RV free wall (50 × Third-degree AVB 17 mm)	RV along IVS (16 × First-degree AVB and 25 × 28 mm) complete RBBB wit intermittent third-d AVB	IVS	IVS Third-degree AVB
Literature search of CS masses from PubMed	Age Sex Presentation	 Weakness, light-headedness, and palpitations 	As	M New-onset syncope	M Dyspnoea on exertion	M Palpitations and syncope	Ă	M Dyspnoea on exertion	Dyspnoea on exertion	Dyspnoea on exertion	- Not mentioned
ture	Age S	29 F	33 F	45 N		45 P	40 F	33	52 F	20 F	71 F
Table 1 Litera		Joffe et al. 1995 ⁴	Scatarige and Fishman 2000 ⁵		Uchida et <i>al.</i> 2011 ⁷ 39	Deshmukh et <i>al.</i> 2012 ⁸	et al.	Bertic, Tandon, and Wisenberg 2016 ¹⁰	t al.	Park et <i>al.</i> 2022 ¹²	Asakura et <i>al.</i> 2022 ¹³

Details of the 10 case reports identified. AVB, atrioventricular block; CS, cardiac sarcoidosis; CMR, cardiac magnetic resonance imaging; IVS, interventricular septum; H&E, haematoxylin and eosin; FDG-cPET, ¹⁸F-fluorodeoxyglucose-positron cardiac positron emission tomography; RA, right atrium; RV, right ventricle; LA, left atrium; LV, left entricle.

she underwent surgical resection of both masses. The pathology report confirmed non-caseating granulomas (*Figure 2C* and *D*). Grocott's methenamine silver and acid-fast bacilli stains from the biopsy were negative. Infectious serology markers including rapid plasma reagin (RPR), HIV, Lyme, Interferon Gamma Release Assay (IGRA), and fungal antigens were negative. An ophthalmological evaluation showed no evidence of ocular involvement. She was therefore diagnosed with isolated CS.

She was initiated on oral prednisone 30 mg daily along with trimethoprim–sulfamethoxazole three times weekly for *Pneumocystis jirovecii* prophylaxis. Prior to discharge, a dual-chamber implantable cardioverter defibrillator (ICD) was implanted. Over the next few weeks, prednisone was weaned and infliximab was added given the degree of cardiac involvement. Shortly after, methotrexate was added to prevent human antichimeric antibody (HACA) formation. She tolerated these medications well without any major adverse reactions.

At 4 months from initial presentation, her device was interrogated and demonstrated no atrial or ventricular arrhythmias. At 6 months, she had a repeat TTE and FDG-cPET, which demonstrated a LVEF > 65% and that the initial FDG-avid lesions in the right atria were no longer visible (*Figure 3*).

Discussion

Cardiac sarcoidosis masses are extremely rarely reported. Our search of PubMed using the Boolean phrases 'sarcoid* AND mass AND (cardia* OR atri* OR ventric*)' yielded an initial 103 results; however, only 10 of these items were true reports of CS masses (*Table 1*).^{4–13} All of the patients in these cases presented with either AVB and/or ventricular arrhythmia, AVB being more common. The majority (60%) of masses involved the interventricular septum. All the cases that included their treatment approach utilized steroids, and one case performed surgical resection though no rationale was provided.⁶ Of the cases that discussed treatment response, a majority (83%) demonstrated improvement either by reduction in mass size or resolution of AVB or arrhythmia.

The differential diagnosis for intracardiac masses includes vegetation, thrombus, primary neoplasms (especially myxoma or angiosarcoma), secondary neoplasms, CS, or implanted devices (e.g. device lead and prosthetic device). Like many intracardiac tumours, a definitive diagnosis of CS requires histopathologic confirmation. For CS, this means identifying the characteristic non-caseating granulomas in endo- or myocardial tissue and exclusion of other plausible causes.¹⁴ Typically, EMB has low sensitivity of ~20% for CS because of the heterogenous distribution of the disease,¹⁵ as evidenced by the two non-diagnostic EMBs we collected. Therefore, surgical resection may be the only mechanism to acquire a diagnostic myocardial sample and may be considered when the diagnosis remains elusive despite less invasive sampling methods.

There are no guidelines that discuss the management specifically of CS masses, and therefore data must be extrapolated from guidelines on CS. The mainstay therapy is oral glucocorticoids (GC), though there is significant heterogeneity in both the dosing and duration utilized.¹⁶ Glucocorticoids have historically been first-line treatment, though recent guidelines suggest the addition of an oral steroid-sparing agent due to the long-term side effects of GC.¹⁷ However, a recent meta-analysis found a relapse rate of about one-third in both GC monotherapy and combination therapy groups.¹⁶ If the patient does not tolerate or fails GC therapy, the patient should try an oral steroidsparing agent, most commonly methotrexate.¹⁶ TNF- α inhibitors are reserved for further refractory disease,¹⁷ and at least one recent study has shown that TNF- α inhibitor containing regimens decrease $^{18}\text{F-FDG}$ myocardial uptake while improving LVEF.¹⁸ Our patient was transitioned to infliximab early in her treatment course due to the extent of her CS masses.

Following diagnosis of CS, it is unclear if there is a role for mass resection. In management of benign intracardiac tumours, resection is often performed due to the concern for tumour mass effect or fragmentation with embolization.¹⁹ This resection is well tolerated with a good prognosis.²⁰ In our literature search of CS masses, there were no reports of these complications arising, which may in part be attributed to the good responses we identified of CS masses to immunosuppressive therapy. Taken together, these findings suggest that resection has limited therapeutic utility.

Conclusion

Cardiac sarcoidosis is a rare cause of intracardiac mass and should be considered when additional manifestations, especially AVB or ventricular arrhythmias, are present. A broad differential diagnosis may also include vegetation, thrombus, and neoplasm, and thus tissue sample is necessary for a definitive diagnosis. The mainstay of management is immunosuppressive therapy, with the primary role of mass resection being diagnostic as opposed to therapeutic.

Lead author biography



Noah Newman is currently a resident in internal medicine at Emory University in Atlanta, GA, USA interested in pursuing cardiology. He completed medical school at Wake Forest University School of Medicine in 2022.

Consent: The authors confirm that written consent for submission and publication of this case report including images and associated text has been received from the patient in line with the Committee on Publication Ethics (COPE) guidelines.

Conflict of interest: None declared.

Funding: No funding was provided for this project.

Data availability

The data underlying this article are available in the article.

References

- Rice JB, White A, Lopez A, Conway A, Wagh A, Nelson WW, et al. Economic burden of sarcoidosis in a commercially-insured population in the United States. J Med Econ 2017; 20:1048–1055.
- Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. *Circulation* 2015;**131**:624–632.
- Birnie D, Ha AC, Gula LJ, Chakrabarti S, Beanlands RS, Nery P. Cardiac sarcoidosis. Clin Chest Med 2015;36:657–668.
- Joffe II, Lampert C, Jacobs LE, Owen AN, Ioli A, Kotler MN. Cardiac sarcoidosis masquerading as a metastatic tumor: the role of transthoracic and transesophageal echocardiography. J Am Soc Echocardiogr 1995;8:933–937.
- Scatarige JC, Fishman EK. Interventricular septal mass: an unusual manifestation of sarcoidosis demonstrated on helical computed tomography. *Clin Imaging* 2000;24: 344–346.
- Abrishami B, O'Connel C, Sharma O. Cardiac sarcoidosis with presentation of large left atrial mass. *Curr Opin Pulm Med* 2004;**10**:397–400.

- Uchida M, Shinohara T, Takahashi N, Saikawa T. Interventricular septal mass in a patient with cardiac sarcoidosis. J Cardiovasc Electrophysiol 2012;23:433–435.
- 8. Deshmukh A, Sewani A, Sachdeva R. Cardiac sarcoidosis masquerading as syncope with right ventricular septal mass. J Invasive Cardiol 2012;24:418–419.
- Takahashi Y, Izumi C, Miyake M, Nakajima S, Nishimura S, Kuroda M, et al. Detecting cardiac sarcoidosis with a right atrial mass using transthoracic echocardiography. *Intern Med* 2016;55:359–363.
- Bertic M, Tandon S, Wisenberg G. Right ventricular mass: a rare presentation of cardiac sarcoidosis. Eur Heart J 2016;37:859.
- Fujimoto R, Asano T, Maezawa H, Shimojima H, Tsujiuchi M, Hori Y, et al. Cardiac sarcoidosis mimicking septal tumor with intermittent complete atrioventricular block. *Int Heart J* 2018;59:1473–1479.
- Park I, Atug E, Hoffmann BA, Goldmann BU. Intermittent complete atrioventricular block in a 20-year-old woman with cardiac sarcoidosis: a case report. *Eur Heart J Case Rep* 2022;6:ytac466.
- Asakura K, Minami Y, Nagata T, Koitabashi T, Ako J. Cardiac sarcoidosis accompanied by a tumor-like blush on coronary angiography. J Cardiol Cases 2022;26:21–23.
- Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. *Heart Rhythm* 2014;11:1305–1323.

- Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. *Circulation* 2007;**116**: 2216–2233.
- Stievenart J, Le Guenno G, Ruivard M, Rieu V, André M, Grobost V. Cardiac sarcoidosis: systematic review of the literature on corticosteroid and immunosuppressive therapies. *Eur Respir J* 2022;59:21004495.
- Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, et al. ERS clinical practice guidelines on treatment of sarcoidosis. *Eur Respir J* 2021;58: 20040796.
- Frischknecht L, Schaab J, Schmauch E, Yalamanoglu A, Arnold DD, Schwaiger J, et al. Assessment of treatment response in cardiac sarcoidosis based on myocardial ¹⁸F-FDG uptake. Front Immunol 2023;**14**:1286684.
- Tyebally S, Chen D, Bhattacharyya S, Mughrabi A, Hussain Z, Manisty C, et al. Cardiac tumors: JACC CardioOncology state-of-the-art review. JACC CardioOncol 2020;2: 293–311.
- Keeling IM, Oberwalder P, Anelli-Monti M, Schuchlenz H, Demel U, Tilz GP, et al. Cardiac myxomas: 24 years of experience in 49 patients. *Eur J Cardiothorac Surg* 2002; 22:971–977.